Gottenberg et al. reported in 2016 [5] that RA patients who switch from a TNF inhibitor to any other family of bDMARDs (biological Disease-Modifying AntiRheumatic Drugs) have the best therapeutic outcomes. Here, TNF is linked to rheumatoid arthritis.